Oruka Therapeutics
ORKA
10 hedge funds and large institutions have $873K invested in Oruka Therapeutics in 2013 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, reducing their positions, and 4 closing their positions.
17% less funds holding
Funds holding: 12 → 10 (-2)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
47% less capital invested
Capital invested by funds: $1.66M → $873K (-$783K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$208K |
| 2 |
Renaissance Technologies
New York
|
+$108K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$91.7K |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
+$41.7K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$37.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.28M |
| 2 |
Citigroup
New York
|
-$6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5K |
| 4 |
U
UBS
Zurich,
Switzerland
|
-$2.08K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $257K | +$208K | +100 | +1,429% |
|
|
2
Renaissance Technologies
New York
| $150K | +$108K | +52 | +520% |
|
|
3
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $125K | +$91.7K | +44 | +550% |
|
|
BIT
4
BlackRock Institutional Trust
San Francisco,
California
| $115K | +$22.9K | +11 | +30% |
|
5
Bank of America
Charlotte,
North Carolina
| $110K | – | – | – |
|
|
6
Nomura Holdings
Tokyo,
Japan
| $48K | +$41.7K | +20 | New |
|
|
7
HighTower Advisors
Chicago,
Illinois
| $44K | +$37.5K | +18 | New |
|
|
SGH
8
Schonfeld Group Holdings
Jericho,
New York
| $16K | +$14.6K | +7 | New |
|
|
BA
9
BlackRock Advisors
Wilmington,
Delaware
| $5K | – | – | – |
|
10
California Public Employees Retirement System
Sacramento,
California
| $3K | – | – | – |
|
|
SM
11
Sabby Management
Miami Beach,
Florida
| – | -$1.28M | -654 | Closed |
|
|
12
Citigroup
New York
| – | -$6K | -3 | Closed |
|
|
TRCT
13
Tower Research Capital (TRC)
New York
| – | -$5K | -2 | Closed |
|
|
U
14
UBS
Zurich,
Switzerland
| – | -$2.08K | -1 | Closed |
|
ORKA Hedge Fund Activity: Q3 2013 in Review
10 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2013, worth a combined $873K — down 47% from $1.66M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ORKA and 3 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $208K. The largest seller was Sabby Management, exiting entirely with an estimated $1.28M sold.
- 10 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2013, down from 12 in Q2 2013.
- Funds reported $873K of Oruka Therapeutics stock for Q3 2013, down 47% quarter-over-quarter.
- 3 funds opened new Oruka Therapeutics positions in Q3 2013 and 4 closed out, a net change of -1 holder.
- The largest Oruka Therapeutics buyer in Q3 2013 was Vanguard Group, an estimated $208K added.
- The largest Oruka Therapeutics seller in Q3 2013 was Sabby Management, an estimated $1.28M sold.
Based on aggregated 13F filings for Q3 2013.